Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 15.41
(0.92%)
CNY 15.41
(0.92%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 496.11 Million CNY | -9.38% |
| 2022 | 547.48 Million CNY | 12.38% |
| 2021 | 487.15 Million CNY | 52.18% |
| 2020 | 320.1 Million CNY | 78.72% |
| 2019 | 179.11 Million CNY | 134.64% |
| 2018 | 76.33 Million CNY | 423.11% |
| 2017 | 14.59 Million CNY | 8947.88% |
| 2016 | 161.28 Thousand CNY | -61.54% |
| 2015 | 419.32 Thousand CNY | 401.72% |
| 2014 | 83.57 Thousand CNY | -83.22% |
| 2013 | 498.16 Thousand CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 154.28 Million CNY | 117.92% |
| 2024 Q1 | 70.79 Million CNY | -50.77% |
| 2024 Q3 | 159.74 Million CNY | 3.54% |
| 2023 Q4 | 143.81 Million CNY | 20.76% |
| 2023 Q3 | 119.09 Million CNY | -28.39% |
| 2023 FY | 496.11 Million CNY | -9.38% |
| 2023 Q1 | 66.87 Million CNY | -62.16% |
| 2023 Q2 | 166.32 Million CNY | 148.73% |
| 2022 Q2 | 179.17 Million CNY | 234.68% |
| 2022 Q1 | 53.53 Million CNY | -73.55% |
| 2022 FY | 547.48 Million CNY | 12.38% |
| 2022 Q4 | 176.7 Million CNY | 27.98% |
| 2022 Q3 | 138.06 Million CNY | -22.94% |
| 2021 Q2 | 105.67 Million CNY | 66.59% |
| 2021 Q4 | 202.38 Million CNY | 75.0% |
| 2021 Q1 | 63.43 Million CNY | -47.14% |
| 2021 FY | 487.15 Million CNY | 52.18% |
| 2021 Q3 | 115.64 Million CNY | 9.43% |
| 2020 Q2 | 82.63 Million CNY | 186.44% |
| 2020 FY | 320.1 Million CNY | 78.72% |
| 2020 Q3 | 88.59 Million CNY | 7.21% |
| 2020 Q4 | 120.02 Million CNY | 35.46% |
| 2020 Q1 | 28.84 Million CNY | -58.19% |
| 2019 Q1 | 9.4 Million CNY | 0.0% |
| 2019 FY | 179.11 Million CNY | 134.64% |
| 2019 Q4 | 69 Million CNY | 0.0% |
| 2018 Q1 | 12.4 Million CNY | -34.28% |
| 2018 Q2 | 12.4 Million CNY | 0.0% |
| 2018 FY | 76.33 Million CNY | 423.11% |
| 2017 Q4 | 18.87 Million CNY | 0.0% |
| 2017 FY | 14.59 Million CNY | 8947.88% |
| 2017 Q1 | 3.45 Million CNY | 4359.3% |
| 2017 Q3 | 18.87 Million CNY | 446.44% |
| 2017 Q2 | 3.45 Million CNY | 0.0% |
| 2016 Q1 | 3189.00 CNY | -95.0% |
| 2016 Q4 | 77.45 Thousand CNY | 0.0% |
| 2016 FY | 161.28 Thousand CNY | -61.54% |
| 2016 Q3 | 77.45 Thousand CNY | 2329.49% |
| 2016 Q2 | 3188.00 CNY | -0.03% |
| 2015 Q3 | 63.76 Thousand CNY | -56.29% |
| 2015 Q2 | 145.89 Thousand CNY | -0.0% |
| 2015 Q1 | 145.89 Thousand CNY | 0.0% |
| 2015 FY | 419.32 Thousand CNY | 401.72% |
| 2015 Q4 | 63.76 Thousand CNY | 0.0% |
| 2014 FY | 83.57 Thousand CNY | -83.22% |
| 2013 FY | 498.16 Thousand CNY | 0.0% |